Valneva SE (VALN)

NASDAQ: VALN · IEX Real-Time Price · USD
-0.59 (-2.75%)
At close: Aug 11, 2022 4:00 PM
-0.15 (-0.72%)
Pre-market: Aug 12, 2022 7:48 AM EDT
Market Cap 1.22B
Revenue (ttm) 395.55M
Net Income (ttm) -83.44M
Shares Out 58.61M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,702
Open 20.29
Previous Close 21.42
Day's Range 20.22 - 21.20
52-Week Range 13.71 - 67.84
Beta 0.93
Analysts Hold
Price Target 29.89 (+43.5%)
Earnings Date Aug 9, 2022

About VALN

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SA... [Read more...]

Industry Biotechnology
IPO Date May 6, 2021
CEO Thomas Lingelbach
Employees 762
Stock Exchange NASDAQ
Ticker Symbol VALN
Full Company Profile

Financial Performance

In 2021, Valneva SE's revenue was 348.09 million, an increase of 215.52% compared to the previous year's 110.32 million. Losses were -73.43 million, 14.0% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for VALN stock is "Hold." The 12-month stock price forecast is 29.89, which is an increase of 43.49% from the latest price.

Price Target
(43.49% upside)
Analyst Consensus: Hold
Stock Forecasts


Valneva cuts full-year outlook on lower COVID-19 vaccine sales

Vaccine developer Valneva on Thursday cut its full-year revenue outlook to account for lower orders of its COVID-19 vaccine after both the European Union and the UK walked away from supply contracts wor...

Valneva Reports H1 2022 Results and Provides Corporate Updates

Excellent progress on late-stage clinical programs

Pfizer, Valneva begin major test of first possible Lyme vaccine in 20 years

DUNCANSVILLE, Pa. — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years — in hopes of better fighting the tick-bor...

Other symbols: PFE

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

NEW YORK & SAINT-HERBLAIN, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against...

Other symbols: PFE

Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva's Inactivated COVID-19 ...

Saint- Herb lain (France ) , August 1 , 2 02 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the signing of the amendment to its Advance Purchase Agreemen...

Other symbols: DVAX

European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 Vaccine

European Commission to order 1.25 million doses of Valneva's whole-virus COVID-19 vaccine VLA2001 in 2022

Other symbols: DVAX

This Biotech Company Is Soaring; Do Not Be Left Out.

Valneva (NASDAQ: VALN) has had a good run this week. It soared 49% at the beginning of trading day Monday and has continued its positive ride.

Other symbols: PFE

Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe

Other symbols: DVAX

Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

Saint - Herblain ( France), June 24 , 202 2 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board w...

Valneva and Pfizer Announce Closing of Equity Investment

Saint- Herblain (France) and New York, June 2 3 , 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equit...

Other symbols: PFE

Valneva announces resumption of trading of its ordinary shares on Euronext Paris

Saint - Herblain ( France), June 2 3 , 202 2 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces the resumption of trading of its ordinary shares on the regulated m...

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in E...

Saint Herblain (France ), June 23 , 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

Other symbols: DVAX

Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?

Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

Why Shares Of Valneva SE Are Soaring Today

Valneva SE (NASDAQ: VALN) shares are trading higher after the company and Pfizer announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and L...

This biotech stock is up 100% on Tuesday: here's the catalyst

Pfizer Inc (NYSE: PFE), on Tuesday, doubled down on its partnership with Valneva SE (NASDAQ: VALN) to develop a vaccine for Lyme disease. Shares of the French biotech firm are up nearly 100% this morning.

Other symbols: PFE

Why Is Valneva (VALN) Stock Up 85% Today?

Valneva (VALN) stock is rocketing higher on Tuesday following news that Pfizer (PFE) is taking a stake in the vaccine company. The post Why Is Valneva (VALN) Stock Up 85% Today?

The Shopify Split Is Just Days Away, but This Tiny Nasdaq Stock Is Soaring Right Now

Markets looked poised for a rebound on Tuesday.

Other symbols: SHOP

Pfizer makes equity investment in Valneva as they prepare for Phase 3 trial of Lyme disease vaccine candidate

U.S.-listed shares of Valneva VALN, -13.47% soared 81.9% in premarket trading on Tuesday, the day after Pfizer Inc. PFE, -2.00% announced a $95 million equity investment in Valneva as part of a previous...

Other symbols: PFE

Why Are Valneva Shares Rallying Today

Pfizer Inc (NYSE: PFE) will invest €90.5 million ($95 million) for an 8.1% stake in Valneva SE (NASDAQ: VALN), as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15. P...

Pfizer To Buy 8.1% Stake In French Vaccines Company Valneva

The U.S. pharmaceuticals group will invest €90.5 million ($95.25 million) in Valneva.

Other symbols: PFE

Pfizer to buy 8.1% of capital of vaccines company Valneva

French specialty vaccine company Valneva and U.S. healthcare giant Pfizer said they had entered an equity subscription agreement under which Pfizer will invest 90.5 million euros ($95.24 million) in Val...

Other symbols: PFE

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme D...

SAINT-HERBLAIN, France & NEW YORK--(BUSINESS WIRE)--Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into a...

Other symbols: PFE

Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why

Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine p...

Valneva Announces Settlement Agreement with the UK Government

Saint- Herb lain (France ) , June 15 , 202 2 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a settlement agreement with the Gove...

Other symbols: DVAX

Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe

Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.